Bio‑Rad Insider Buys Shares as New Analytics Partnership Fuels Investor Confidence
Bi‑Rad insider Di Vincenzo’s cautious buy‑sell mix signals steady optimism about its new analytics‑driven oncology pipeline – a potential buy‑the‑dip for investors.
3 minutes to read